Basic Medical College, Zhejiang Chinese Medical University, Hangzhou310053, People's Republic of China.
Section of Integrative Medicine, Zhejiang Provincial People's Hospital, Hangzhou310053, People's Republic of China.
Public Health Nutr. 2024 Apr 11;27(1):e118. doi: 10.1017/S1368980024000776.
OBJECTIVE: This study aimed to evaluate the methodological quality of existing meta-analyses (MA) and the quality of evidence for outcome indicators to provide an updated overview of the evidence concerning the therapeutic efficacy of the Mediterranean diet (MD) for various types of CVD. DESIGN: We conducted comprehensive searches of PubMed, Cochrane Library, and Embase databases. The quality of the MA was assessed using the A Measurement Tool to Assess Systematic Reviews 2 (AMSTAR 2) checklist, while the Grading of Recommendations Assessment, Development and Evaluation (GRADE) evidence evaluation system was employed to evaluate the quality of evidence for significant outcomes. SETTING: The CVD remains a significant contributor to global mortality. Multiple MA have consistently demonstrated the efficacy of medical interventions in managing CVD. However, due to variations in the scope, quality and outcomes of these reviews, definitive conclusions are yet to be established. PARTICIPANTS: This study included five randomized trials and twelve non-randomized studies, with a combined participant population of 716 318. RESULTS: The AMSTAR 2 checklist revealed that 54·55 % of the studies demonstrated high quality, while 9·09 % exhibited low quality, and 36·36 % were deemed critically low quality. Additionally, there was moderate evidence supporting a positive correlation between MD and CHD/acute myocardial infarction, stroke, heart failure, cardiovascular events, coronary events and major adverse cardiovascular events. CONCLUSIONS: This study indicates that although recognizing the potential efficacy of MD in managing CVD, the quality of the methodology and the evidence for the outcome indicators remain unsatisfactory.
目的:本研究旨在评估现有荟萃分析(MA)的方法学质量和结局指标的证据质量,为治疗地中海饮食(MD)对各种心血管疾病(CVD)疗效的证据提供最新概述。
设计:我们全面检索了 PubMed、Cochrane 图书馆和 Embase 数据库。使用评估系统评价的测量工具(AMSTAR 2)检查表评估 MA 的质量,而使用推荐评估、制定与评价(GRADE)证据评价系统评估重要结局的证据质量。
背景:CVD 仍然是全球死亡率的主要原因。多项 MA 一致表明,医学干预在管理 CVD 方面具有疗效。然而,由于这些综述的范围、质量和结局存在差异,因此尚未得出明确的结论。
参与者:本研究纳入了五项随机试验和十二项非随机研究,总参与者人群为 716318 人。
结果:AMSTAR 2 检查表显示,54.55%的研究质量较高,9.09%的研究质量较低,36.36%的研究质量较差。此外,有中度证据支持 MD 与冠心病/急性心肌梗死、中风、心力衰竭、心血管事件、冠状动脉事件和主要不良心血管事件之间存在正相关关系。
结论:本研究表明,尽管认识到 MD 对 CVD 的潜在疗效,但方法学质量和结局指标的证据仍不尽人意。
Public Health Nutr. 2024-4-11
Cochrane Database Syst Rev. 2022-2-1
Cochrane Database Syst Rev. 2019-3-13
Evid Based Complement Alternat Med. 2021-7-17
Cochrane Database Syst Rev. 2022-2-24
Cochrane Database Syst Rev. 2016-1-29
Cochrane Database Syst Rev. 2018-11-29
J Health Popul Nutr. 2025-6-14
Bull World Health Organ. 2023-4-1
Nutr Metab Cardiovasc Dis. 2023-1
Ann Intern Med. 2022-9